|
This drug could be worth watching for HER2. Certainly someone with better biochemistry knowledge than mine could do a little reading up. It has had some impressive results in animal models and now in human trials.
My wife is a patient at the Royal Marsden where the trials are running and about 6 months ago I did a bit of research on Kosan and their polyketide products.
As I understand it, 17AAG blocks Hsp90 and interferes with the process of folding of oncoproteins - and if the cancer cell can't synthesise proteins, it can't grow. I believe that one of the main client proteins of Hsp90 is HER2 and that the more general pathway being interfered involves PI3Kinase inhibition. A pathway which crops up frequently in HER2 targetted therapies.
Next time I'm in the Marsden I'll interrogate one of the oncs involved in the trial - but not due to go back for three weeks.
J
|